secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001628280-23-028555
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex Q2 2023: Net sales $20.3M (+21%), positive Adj EBITDA, raises FY23 guidance to ≥15% growth
--------------------------------------------------------------------------------

- Net sales $20.3M, up 21% YoY; Tru Niagen sales $16.9M (+16%).
- Net loss narrowed to $2.2M ($0.03/sh) from $6.4M ($0.09/sh) a year ago.
- Gross margin 60.8% (+80bps); sales & marketing expense improved 1,830 bps to 29.6% of sales.
- Positive Adjusted EBITDA of $0.2M vs negative $4.7M in Q2 2022; positive operating cash flows.
- Raised FY2023 revenue outlook by 2.5% to at least 15% YoY growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023028555/0001628280-23-028555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023028555/cdxc-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer